Cipla rises 4% on asthma drug launch, Kotak says buy – Moneycontrol.com


Moneycontrol.com

Cipla rises 4% on asthma drug launch, Kotak says buy
Moneycontrol.com
Shares of Cipla surged 4 percent intraday on Thursday on launch of asthma treatment medicine. In partnership with Sandoz, the drug company has launched Pulmicort Respules 1mg /ml version which is used for long-term treatment of asthma and prevention …
Cipla surges after its partner Sandoz received USFDA nod for a key drugBusiness Standard

all 4 news articles »

View full post on asthma – Google News